Market overview
The global metered dose inhaler market is worth USD 17.9 bn in 2026 and is forecast to reach USD 29.1 bn by 2036, growing at a 5.0% CAGR. United States is the largest country market and Combination inhalers is the largest by drug class segment.
| Scope | Pressurised metered dose inhalers delivering asthma and COPD drugs, including bronchodilators, corticosteroids and combination inhalers, branded and generic. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 17.0 bn |
| Value 2026 | USD 17.9 bn |
| Value 2036 | USD 29.1 bn |
| CAGR 2026-2036 | 5.0% |
| Volume 2026 | 679 million units |
| Volume 2036 | 1,052 million units |
| Average price 2026 | USD 26.3 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Metered Dose Inhaler market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 17.9 bn |
| 2027 | USD 18.7 bn |
| 2028 | USD 19.7 bn |
| 2029 | USD 20.7 bn |
| 2030 | USD 21.7 bn |
| 2031 | USD 22.8 bn |
| 2032 | USD 23.9 bn |
| 2033 | USD 25.1 bn |
| 2034 | USD 26.4 bn |
| 2035 | USD 27.7 bn |
| 2036 | USD 29.1 bn |
Metered Dose Inhaler market segmentation
By drug class
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Short-acting bronchodilators | 24.0% | 18.4% | USD 4.3 bn | 2.2% |
| Long-acting bronchodilators | 18.0% | 19.3% | USD 3.2 bn | 5.7% |
| Inhaled corticosteroids | 20.0% | 17.7% | USD 3.6 bn | 3.7% |
| Combination inhalers | 38.0% | 44.7% | USD 6.8 bn | 6.7% |
By access
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Branded | 62.0% | 54.5% | USD 11.1 bn | 3.6% |
| Generic | 32.0% | 39.1% | USD 5.7 bn | 7.1% |
| Authorised generic | 6.0% | 6.4% | USD 1.1 bn | 5.6% |
By dose counter
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Without dose counter | 44.0% | 30.0% | USD 7.9 bn | 1.1% |
| Integrated dose counter | 42.0% | 52.0% | USD 7.5 bn | 7.3% |
| Add-on dose counter | 14.0% | 18.0% | USD 2.5 bn | 7.7% |
By therapy area
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Asthma | 48.0% | 46.0% | USD 8.6 bn | 4.5% |
| COPD | 44.0% | 44.0% | USD 7.9 bn | 5.0% |
| Other respiratory conditions | 8.0% | 10.0% | USD 1.4 bn | 7.4% |
By propellant
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Legacy HFA propellant | 72.0% | 30.0% | USD 12.9 bn | -3.8% |
| Low-warming HFA propellant | 20.0% | 40.0% | USD 3.6 bn | 12.5% |
| Next-generation low-impact propellants | 8.0% | 30.0% | USD 1.4 bn | 19.8% |
Top 25 countries for metered dose inhaler by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 85.0% of 2026 revenue and the 25 countries below together hold 95.8%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 7.5 bn | 42.0% | USD 11.6 bn | 4.4% |
| 2 | China | USD 1.8 bn | 10.0% | USD 3.7 bn | 7.5% |
| 3 | Japan | USD 1.1 bn | 6.0% | USD 1.5 bn | 3.5% |
| 4 | Germany | USD 892 mn | 5.0% | USD 1.3 bn | 3.9% |
| 5 | United Kingdom | USD 892 mn | 5.0% | USD 1.3 bn | 3.9% |
| 6 | France | USD 714 mn | 4.0% | USD 1.0 bn | 3.9% |
| 7 | India | USD 714 mn | 4.0% | USD 1.8 bn | 9.5% |
| 8 | Italy | USD 536 mn | 3.0% | USD 785 mn | 3.9% |
| 9 | Canada | USD 536 mn | 3.0% | USD 814 mn | 4.3% |
| 10 | Brazil | USD 536 mn | 3.0% | USD 960 mn | 6.0% |
| 11 | Spain | USD 302 mn | 1.7% | USD 488 mn | 4.9% |
| 12 | Australia | USD 270 mn | 1.5% | USD 436 mn | 4.9% |
| 13 | South Korea | USD 232 mn | 1.3% | USD 375 mn | 4.9% |
| 14 | Netherlands | USD 186 mn | 1.0% | USD 299 mn | 4.9% |
| 15 | Mexico | USD 154 mn | 0.9% | USD 247 mn | 4.9% |
| 16 | Turkey | USD 143 mn | 0.8% | USD 230 mn | 4.9% |
| 17 | Russia | USD 118 mn | 0.7% | USD 192 mn | 5.0% |
| 18 | Poland | USD 105 mn | 0.6% | USD 172 mn | 5.0% |
| 19 | Saudi Arabia | USD 87 mn | 0.5% | USD 140 mn | 4.8% |
| 20 | Sweden | USD 79 mn | 0.4% | USD 125 mn | 4.8% |
| 21 | Argentina | USD 70 mn | 0.4% | USD 113 mn | 5.0% |
| 22 | Belgium | USD 55 mn | 0.3% | USD 90 mn | 5.0% |
| 23 | Switzerland | USD 50 mn | 0.3% | USD 81 mn | 5.0% |
| 24 | Indonesia | USD 45 mn | 0.2% | USD 73 mn | 5.0% |
| 25 | South Africa | USD 37 mn | 0.2% | USD 61 mn | 5.0% |
| Rest of world | USD 746 mn | 4.2% | USD 1.2 bn | 5.0% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- GSK
- AstraZeneca
- Chiesi
- Teva Pharmaceutical
- Cipla
- Viatris
- Boehringer Ingelheim
Group 2: Regional and specialist players
- Lupin
- Glenmark
- Orion
- Zydus Lifesciences
- Hikma
- Amneal
- Sun Pharmaceutical
- Aptar Pharma
Group 3: Emerging and niche players
- Kindeva
- Presspart
- Koura
- Recipharm
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the metered dose inhaler market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 5.0% is calculated from the resulting values.
The market is divided by drug class, by access, by dose counter, by therapy area, by propellant. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the metered dose inhaler market?
The global metered dose inhaler market is estimated at USD 17.0 bn in 2025 and USD 17.9 bn in 2026.
How fast will the metered dose inhaler market grow?
It is forecast to reach USD 29.1 bn by 2036, a compound annual growth rate of 5.0% from 2026, an increase of USD 11.2 bn.
Which country is the largest market for metered dose inhaler?
United States is the largest market by revenue at USD 7.5 bn in 2026, 42.0% of the global total. The three largest countries together hold 58.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 9.5% a year from 2026 to 2036.
Which metered dose inhaler segment is largest?
In the by drug class split, Combination inhalers is the largest segment with 38.0% of 2026 revenue.
Who are the leading metered dose inhaler companies?
Global leaders include GSK, AstraZeneca, Chiesi, Teva Pharmaceutical.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Surgical RoboticsUSD 17.7 bn · 14.0% CAGR
- Fill FinishUSD 17.6 bn · 9.0% CAGR
- Insulin DeliveryUSD 16.8 bn · 8.0% CAGR
- Nasal Drug DeliveryUSD 19.1 bn · 6.2% CAGR
- Downstream ProcessingUSD 16.6 bn · 10.5% CAGR
- Antibody Drug ConjugatesUSD 16.5 bn · 14.5% CAGR
- Pharmaceutical GlassUSD 19.4 bn · 7.2% CAGR
- Next Generation SequencingUSD 16.4 bn · 13.0% CAGR